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Abstract
Given the rise of bacterial resistance against antibiotics, we urgently need alternative 
strategies to fight infections. Some propose we should disarm rather than kill bacteria, 
through targeted disruption of their virulence factors. It is assumed that this approach 
(i) induces weak selection for resistance because it should only minimally impact bac-
terial fitness, and (ii) is specific, only interfering with the virulence factor in question. 
Given that pathogenicity emerges from complex interactions between pathogens, 
hosts and their environment, such assumptions may be unrealistic. To address this 
issue in a test case, we conducted experiments with the opportunistic human patho-
gen Pseudomonas aeruginosa, where we manipulated the availability of a virulence fac-
tor, the iron- scavenging pyoverdine, within the insect host Galleria mellonella. We 
observed that pyoverdine availability was not stringently predictive of virulence and 
affected bacterial fitness in nonlinear ways. We show that this complexity could partly 
arise because pyoverdine availability affects host responses and alters the expression 
of regulatorily linked virulence factors. Our results reveal that virulence factor ma-
nipulation feeds back on pathogen and host behaviour, which in turn affects virulence. 
Our findings highlight that realizing effective and evolutionarily robust antivirulence 
therapies will ultimately require deeper engagement with the intrinsic complexity of 
host–pathogen systems.
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O R I G I N A L  A R T I C L E
Manipulating virulence factor availability can have complex 
consequences for infections
Michael Weigert1,2 | Adin Ross-Gillespie1,3 | Anne Leinweber1 | Gabriella Pessi1 |  
Sam P. Brown4 | Rolf Kümmerli1
1  | INTRODUCTION
The pervasive idea that virulence—the damage a host experiences 
during infection—follows more or less directly from pathogen load 
has shaped our view of infectious disease since the early days of germ 
theory (Anderson & May, 1979; Bastian, 1875; Evans, 1976; Frank, 
1996; Pasteur, 1880; Stearns & Koella, 2008) and has underpinned 
our clinical quest to eradicate harmful microbes (Allison, Brynildsen, 
& Collins, 2011; Dagan, Klugman, Craig, & Baquero, 2001; Russell, 
2011). However, advances over the years have revealed that the 
severity of an infectious disease depends on much more than just 
the sheer number of pathogens present; rather, it derives from com-
plex interactions between the pathogen, its host and the prevailing 
abiotic and biotic ecological conditions (Bull & Lauring, 2014; de 
Lorenzo, 2015; Méthot & Alizon, 2014; Schmid- Hempel, 2011). In 
other words, a microbe’s pathogenicity is not so much about what 
it is and how abundant it is, but what it does, when it does it and to 
whom.
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These insights have important consequences for antibacterial 
therapies that seek to control rather than eradicate infections (Vale 
et al., 2016). In particular, “antivirulence” approaches have been seen 
as promising alternatives to classic antibiotics (Allen, Popat, Diggle, & 
Brown, 2014; Cegelski, Marshall, Eldridge, & Hultgren, 2008; Rasko 
& Sperandio, 2010; Vale et al., 2016). Such therapies seek to disarm 
rather than kill pathogens and do so by inhibiting the synthesis or 
the functioning of virulence factors (e.g. toxins, tissue- degrading en-
zymes, iron- scavenging siderophores, quorum sensing signals; Rahme 
et al., 1995; Miethke & Marahiel, 2007; Nadal Jimenez et al., 2012; 
LaSarre & Federle, 2013). The appeal of this strategy is that any ef-
fects on bacterial fitness should be relatively minor, and therefore, 
such treatments should induce only relatively weak selection for re-
sistance (André & Godelle, 2005; Pepper, 2012). However, given the 
above- mentioned complexities intrinsic in infectious diseases, we 
can expect that in many cases, a given antivirulence drug will have 
effects that extend beyond simply quenching the targeted virulence 
factor. We might have all sorts of unanticipated secondary effects on 
the behaviour of the pathogen and its host. For example, the suppres-
sion of one virulence factor could pleiotropically affect the regulation 
of another virulence factor due to regulatory linkage at the genetic 
level (Balasubramanian, Schneper, Kumari, & Mathee, 2013; García- 
Contreras et al., 2014; Herrera, García- Arriaza, Pariente, Escarmís, & 
Domingo, 2007; Nadal Jimenez et al., 2012). Furthermore, virulence 
factors often serve as cues for hosts to mount an immune response 
(Miyashita, Takahashi, Ishii, Sekimizu, & Kaito, 2015; Park et al., 2014; 
Schmid- Hempel, 2005; Taszlow & Wojda, 2015), so interfering with 
some virulence factors’ availability could indirectly modulate host 
responses.
In the light of this inherent complexity, it seems challenging to 
predict how a specific antivirulence therapy will likely affect bacterial 
load and treatment efficacy. If indeed the treatment causes second-
ary effects of the sort envisaged above, we might need to carefully 
re- evaluate previous claims on the evolutionary robustness of such 
therapies. Complex interactions between pathogen and host fac-
tors could bring into play a multitude of different traits, all of which 
would be potential targets upon which natural selection could act on. 
Consequently, there could still be considerable selection for pathogen 
variants that are resistant to the treatment and/or become more viru-
lent (Vale, Fenton, & Brown, 2014; Vale et al., 2016).
Here, we use the opportunistic human pathogen Pseudomonas 
aeruginosa as a test case to investigate the consequences of manip-
ulating virulence factor availability. This bacterium relies on a number 
of virulence factors to establish infections in animals and humans, in-
cluding immune- compromised cystic fibrosis patients (Lyczak, Cannon, 
& Pier, 2002; Papaioannou, Utari, & Quax, 2013; Rahme et al., 2000). 
One particularly well- studied virulence factor is pyoverdine, a sid-
erophore secreted into the local environment to scavenge iron from 
host tissue (Cornelis & Dingemans, 2013; Harrison, Browning, Vos, 
& Buckling, 2006; Meyer, Neely, Stintzi, Georges, & Holder, 1996). 
Pyoverdine is a multifunctional molecule. It can be shared as public 
good between cells for iron uptake to stimulate growth and biofilm 
formation (Banin et al., 2008; Buckling et al., 2007). It is also used as a 
signalling molecule to control its own expression, and the synthesis of 
two additional virulence factors, exotoxin A and protease IV (Lamont, 
Beare, Ochsner, Vasil, & Vasil, 2002). Additionally, it can act as a 
toxin by interfering with mitochondrial iron homoeostasis (Kirienko, 
Ausubel, & Ruvkun, 2015). For all those reasons, pyoverdine has 
been identified as a suitable target for antivirulence therapies (Banin 
et al., 2008; Bonchi, Frangipani, Imperi, & Visca, 2015; Bonchi, Imperi, 
Minandri, Visca, & Frangipani, 2014; Kaneko, Thoendel, Olakanmi, 
Britigan, & Singh, 2007; Lamont et al., 2002; Ross- Gillespie, Weigert, 
Brown, & Kümmerli, 2014; Visca, Imperi, & Lamont, 2007). In this 
study, we manipulated the availability of pyoverdine in the context of 
experimental infections of greater waxmoth larvae (Galleria mellonella). 
We investigated how interference with this virulence factor affects (i) 
bacterial growth within the host; (ii) the host’s response to infections; 
(iii) the pleiotropic regulatory links to other virulence factors; and (iv) 
how these factors combine and determine the overall level of viru-
lence the host experiences. Building from previous work, we reduced 
the in vivo availability of pyoverdine by supplementing bacterial inoc-
ula with gallium, an iron mimic that inactivates pyoverdine molecules 
by binding irreversibly to them in place of iron (Kaneko et al., 2007; 
Ross- Gillespie et al., 2014). In addition, we also explored pathogen and 
host responses under conditions of increased pyoverdine availabilities. 
This allows us to test more generally how predictive virulence factor 
availability is for disease severity.
2  | MATERIALS AND METHODS
2.1 | Strains and media
Our experiments featured the clinical isolate P. aeruginosa PAO1 
(ATCC 15692), a pyoverdine- defective knockout strain derived from 
this wild type (PAO1ΔpvdD), and three derivatives of these strains 
engineered via chromosomal insertion (attTn7::ptac- gfp, attTn7::ptac- 
mcherry) to constitutively express fluorescent proteins—that is PAO1- 
gfp, PAO1- mcherry and PAO1ΔpvdD- gfp. Overnight cultures were 
grown in 8 ml Luria–Bertani (LB) medium in 50- ml Falcon tubes and 
incubated at 37°C, 200 rpm for 16–18 hr. For all experiments, we sub-
sequently diluted the overnight cultures in 0.8% NaCl saline solution. 
For in vitro assays, we used iron- limited CAA medium (per litre: 5 g 
casamino acids, 1.18 g K2HPO4*3H2O, 0.25 g MgSO4*7H2O, 100 μg/ml 
human apotransferrin, 20 mM NaHCO3 and 25 mM HEPES buffer). 
Human apotransferrin in combination with NaHCO3 (as cofactor) is 
a strong iron chelator, which prevents non- siderophore- mediated 
iron uptake. All chemicals were purchased from Sigma- Aldrich, 
Switzerland. Pyoverdine was isolated using the protocol by Meyer 
et al. (1997).
2.2 | Manipulation of pyoverdine availability
In both our in vitro and in vivo assays, we reduced and increased pyo-
verdine availability by supplementing bacterial inocula with, respec-
tively, either gallium nitrate or purified pyoverdine. Gallium is an iron 
mimic that inactivates pyoverdine molecules by binding irreversibly 
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to them in place of iron. It thereby lowers pyoverdine availability in 
a dose- dependent manner (Kaneko et al., 2007; Ross- Gillespie et al., 
2014). The addition of pyoverdine immediately increases availability 
after inoculation, which has been shown to stimulate bacterial growth 
in vitro (Kümmerli & Brown, 2010). For in vitro experiments, we varied 
gallium and pyoverdine concentrations from 5 to 250 μM. For in vivo 
experiments, we prepared inocula with 10- fold higher concentrations, 
as we assumed that upon injection into a host larva’s haemolymph (a 
total volume of approximately 100 μl; Harding, Schroeder, Collins, & 
Frankel, 2013), our infection inoculum (a 10 μl volume) would become 
diluted by a factor of approximately ten. Hereafter we report in vivo 
concentrations as estimated final concentrations, adjusted to reflect 
this assumed 10- fold dilution.
2.3 | In vitro growth and pyoverdine assays
To assess how our treatment regimes affect pyoverdine availability 
and bacterial growth, we performed in vitro growth assays. Overnight 
LB cultures (PAO1 and PAO1ΔpvdD) were washed twice and stand-
ardized for optical density (OD = 2) and then inoculated at 10−3 di-
lution to iron- limited CAA supplemented with either gallium nitrate 
(Ga(NO3)3; 5, 10, 20, 50 and 250 μM) or purified pyoverdine (same 
concentrations), to respectively reduce or enhance the availability of 
pyoverdine. All conditions were carried out in fourfold replication. 
Growth was tracked over 24 hr (37°C) in 200 μl cultures in 96- well 
plates (BD Falcon, Switzerland) using a Tecan Infinite M- 200 plate 
reader (Tecan Group Ltd, Switzerland). We measured OD at 600 nm 
and pyoverdine- associated fluorescence (400 ex | 460 em), every 
15 min following brief shaking of the plate (30s, 3.5 mm orbital dis-
placement). As gallium increases pyoverdine fluorescence, we cor-
rected fluorescence values using a previously published calibration 
curve (Ross- Gillespie et al., 2014).
2.4 | In vivo growth assays
Infections were performed following protocols described in Ross- 
Gillespie et al. (2014). Briefly, final- instar Galleria mellonella larvae, 
standardized for mass and general condition, were surface- sterilized 
with 70% ethanol, inoculated between the posterior prolegs (Hamilton 
syringe; 26s gauge sterile needle) and then individually (randomly) dis-
tributed to the wells of 24- well plate for incubation at 37°C. In vivo 
bacterial growth was assayed as per Ross- Gillespie et al. (2014), using 
GFP fluorescence signal as a proxy for growth. For this reason, we 
infected larvae with bacterial strains harbouring a constitutively ex-
pressed gfp marker (i.e. PAO1- gfp or PAO1ΔpvdD- gfp). Inocula (10 μl) 
contained ~25 colony- forming units (CFU) of either PAO1- gfp sup-
plemented with gallium (50 μM or 250 μM) or pyoverdine (50 μM or 
250 μM), no pyoverdine or the pyoverdine- defective PAO1ΔpvdD- gfp 
as a control treatment. A growth- negative control included the injec-
tion of saline solution. At 17 hr postinfection, larvae (24 per treatment) 
were processed to estimate their bacterial load. Approximately 50% 
of the larvae that had been infected with the wild- type strain were al-
ready dead at this time point. Larvae were individually flash- frozen in 
liquid nitrogen and then ground to fine powder using sterile micropes-
tles. Powderized larval homogenates were resuspended in 1 ml sterile 
H2O and centrifuged at 6300 RCF for 2 min. Thereafter, 200 μl of the 
water- soluble liquid phase of each sample was transferred to a 96- 
well plate and assayed for GFP- associated fluorescence using a Tecan 
Infinite M- 200 plate reader. To examine whether the bacterial load at 
17 hr postinfection is representative of within- host growth dynam-
ics, we repeated the experiment for a subset of treatments (untreated 
wild type, wild type with intermediate (50 μM) gallium or pyoverdine 
concentration, pyoverdine- deficient mutant, saline control). At 13, 15, 
17 and 20 hr, we processed randomly selected larvae (24 per treat-
ment) as described above and measured their bacterial load.
2.5 | Ex vivo growth assays
We investigated the potential influence of host effects on bacterial 
dynamics via ex vivo growth assays in haemolymph. In a first step, we 
primed G. mellonella larvae by inoculating them with bacterial wild- 
type cultures featuring manipulated levels of pyoverdine (by supple-
menting inoculum with either intermediate (50 μM) concentrations 
of gallium or pyoverdine). As controls, we primed larvae by infecting 
them with either the pyoverdine- deficient strain, pyoverdine alone, 
heat- killed wild- type bacteria or the saline control. In a second step, 
we then measured bacterial growth in haemolymph extracted from 
these primed larvae. The priming inocula were administered as per 
the infection protocol described above. Inoculated larvae were dis-
tributed, in groups of 4, to petri dishes and incubated at 37°C. After 
14 hr, the petri dishes were placed on ice for 15 min to anaesthetize 
the larvae prior to haemolymph extraction. A small incision was made 
in the posterior segment using a sterile scalpel, and haemolymph was 
drained with the aid of gentle pressure (Harding et al., 2013). From 
each sample, 25 μl of haemolymph was immediately stabilized with 
15 μl of an ice- cold pH 6.5 cacodylate buffer (10 mM Na- C2H7AsO2 
and 5 mM CaCl2) and 15 μl of a saturated propylthiouracil solution to 
inhibit melanization. Samples were then centrifuged (514 RCF, 2 min) 
to separate the liquid haemolymph fraction from any solid tissue con-
taminants, and 30- μl aliquots were transferred to individual wells of a 
96- well plate, each containing 70 μl of saline solution. To kill the prim-
ing strains and any other bacteria that may have been present in the 
haemolymph as part of the natural larval microbiota, we added gen-
tamicin to the haemolymph/buffer mixture to a final concentration of 
20 μg/ml (a concentration known to kill susceptible P. aeruginosa; Choi 
et al., 2005). Subsequently, we inoculated wells with bacteria from an 
overnight culture (adjusted to an OD = 2 and subsequently diluted 
to 10−4) of a gentamicin- resistant PAO1-mcherry strain (this strain 
showed the same growth pattern as the untagged wild- type strain). 
The plate was transferred to a Tecan Infinite M- 200 plate reader for 
24 hr of incubation at 37°C. Every 15 min, we measured cell density 
(measured via the mCherry- associated fluorescence: 582 ex | 620 em; 
note: using optical density as a proxy for cell density is not reliable in 
this naturally turbid medium). These experiments allowed us to ascer-
tain (i) whether bacterial growth in haemolymph is affected by a host’s 
history of prior infection and (ii) whether the availability of pyoverdine 
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during priming predicts subsequent bacterial growth. Note that re-
sidual pyoverdine from the priming inocula was below detection limit 
after haemolymph extraction, and therefore should not influence later 
bacterial growth patterns.
2.6 | Molecular investigation of pyoverdine- 
mediated pleiotropy
Because pyoverdine is not only a virulence factor but also a signal-
ling molecule, manipulating pyoverdine availability might also affect, 
via interaction with the PvdS iron- starvation sigma factor, the pro-
duction of two additional virulence factors, exotoxin A and protease 
IV (Lamont et al., 2002; Ochsner, Johnson, Lamont, Cunliffe, & Vasil, 
1996; Wilderman et al., 2001). We used qPCR to explore whether 
our extrinsic manipulation of pyoverdine levels could change 
pyoverdine- mediated signalling and therefore pleiotropically affect 
expression of genes for virulence factor production (pvdS, toxA cod-
ing for exotoxin A, prpL (alternative name: piv) coding for protease IV 
and pvdA coding for one of the pyoverdine synthesis enzymes). PAO1 
cells were grown until early- and mid- exponential growth phases in 
20 ml standard CAA (in a sterile 500- ml Erlenmeyer) containing ei-
ther (i) no supplement, (ii) 10 μM Ga(NO3)3 (to reduce pyoverdine 
availability), (iii) 200 μM purified pyoverdine (to increase pyoverdine 
availability) or (iv) 100 μM FeSO4 (our negative control under which 
pyoverdine production should be completely switched off; Kümmerli, 
Jiricny, Clarke, West, & Griffin, 2009). RNA was extracted using a 
modified hot acid phenol protocol and purified as in Pessi et al. (2007, 
2013). Residual DNA in the sample was eliminated using RQ1 RNase- 
free DNase I, and purification was performed using the RNeasy Mini 
Kit (Qiagen). Absence of DNA was verified by PCR using the prim-
ers specified in Table S1, and 40 cycles with the GoTaq Polymerase 
(Promega, Switzerland). RNA quality in the purified samples was 
then assessed using RNA Nano Chips (Agilent 2100 Bioanalyzer; 
RIN (RNA integrity number) >7.6). First- strand cDNA synthesis with 
10 μg of total RNA from each sample was performed with M- MLV 
reverse transcriptase RNase H Minus (Promega) and random prim-
ers (Promega). cDNA was subsequently purified with the MinElute 
PCR Purification Kit (Qiagen). The expression of Pseudomonas aer-
uginosa PAO1 genes PA2399 (pvdD), PA2426 (pvdS), PA1148 (toxA) 
and PA4175 (prpL) was analysed with a Stratagene MX300P instru-
ment (Agilent) using GoTaq qPCR Master Mix (Promega). All PCRs 
were analysed in triplicate with three cDNA dilutions (15, 7.5 and 
3.25 ng) and 0.4 μM of individual primers in a total volume of 25 μl 
per reaction. Primers (Table S1) were designed using Primer3Plus 
(Untergasser et al., 2007) and subsequently verified by PCR. Fold 
changes were calculated using the ΔΔCT method (Pfaffl, 2001) using 
the primary sigma factor rpoD (PA0576) as housekeeping gene for 
data normalization.
2.7 | Virulence assays
Infections were performed as described above. Inocula (10 μl) 
contained ~25 CFU of P. aeruginosa from an overnight culture, 
resuspended in saline solution and supplemented with either gallium 
nitrate (5 μM, 50 μM, 250 μM), pyoverdine (10 μM, 50 μM, 250 μM) 
or neither. Controls included saline- only, gallium- only (50 μM and 
250 μM) and pyoverdine- only inocula (50 μM and 250 μM), and also 
the PAO1ΔpvdD strain, defective for pyoverdine production. The 
vitality of all larvae (i.e. spontaneous movement/response to tactile 
stimulation) was assessed hourly, starting at 10 hr postinjection. Some 
of the larvae (n = 25, 3.14%) either started pupating while under ob-
servation or died prematurely during the first 10 hr postinjection—
presumably as a result of handling—and hence were excluded from 
further analyses.
2.8 | Statistical analysis
We used the functions from the “grofit” R package to fit spline curves 
to the growth and pyoverdine production trajectories. From these 
fitted curves, we extracted growth parameters. In particular, we fo-
cused on growth integrals (areas under curves), which combine infor-
mation from the lag phase, growth rate and yield. Growth integrals 
are particularly useful for nonlogistic growth trajectories as observed 
throughout our experiments.
Survival curves were analysed by fitting parametric Weibull sur-
vival curves with the aid of functions from the “survival” R package 
(Therneau & Grambsch, 2000). From the fitted models, we extracted 
the hazard ratios and used those values to estimate the mortality risk 
of larvae within each treatment. To confirm the robustness of our anal-
ysis, we also performed Cox proportional hazards regression, which 
yielded qualitatively similar results.
We used both parametric and nonparametric statistical models to 
test for treatment effects. Specifically, we used Kendall rank correla-
tion analyses to test for associations between pyoverdine availability, 
growth, host response and virulence. The data from our in vivo and 
ex vivo growth experiments did not meet the criteria of normally dis-
tributed residuals and the homogeneity of variances, which precluded 
the use of parametric statistical tests. For these analyses, we used the 
nonparametric Kruskal–Wallis test. All analyses were performed in R 
3.3.0 (R Development Core Team 2015).
3  | RESULTS
3.1 | Treatment effects on in vitro bacterial 
pyoverdine availability and growth
We first tested whether our treatment regime (i.e. adding gallium to 
quench pyoverdine or supplementing additional pyoverdine) indeed 
altered pyoverdine availability as intended. We found that our treat-
ment regime had a positive linear effect on pyoverdine availability 
(Figure 1a; Kendall’s correlation coefficient: τ = .75, p < .001, meas-
ured during the first 8 hr of the growth period when pyoverdine is 
most needed to overcome iron limitation; Kümmerli & Brown, 2010). 
Moreover, we found that our manipulation of pyoverdine avail-
ability had a significant linear effect on bacterial growth (Figure 1b; 
τ = .93, p < .001): adding gallium reduced growth, while pyoverdine 
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supplementation accelerated growth relative to the unsupplemented 
wild type. Taken together, our in vitro experiments show that our 
treatment scheme successfully manipulates pyoverdine availability 
and that pyoverdine is a growth promoter, essential for bacteria to 
thrive in iron- limited medium.
3.2 | Nonlinear effects of pyoverdine availability on 
in vivo bacterial growth
Pyoverdine availability also had significant effects on bacterial growth 
within the G. mellonella larvae (Kruskal–Wallis test for differences 
between treatments: χ2 = 34.80, p < .001; Figure 2), but the over-
all effect was not linear. Instead, bacterial load peaked in infections 
with the unsupplemented wild type (i.e. at intermediate pyoverdine 
availability). Both the addition of gallium and pyoverdine significantly 
reduced bacterial growth compared to unsupplemented wild- type in-
fections (for gallium 50 and 250 μM combined: χ2 = 8.68, p = .013; 
for pyoverdine 50 and 250 μM combined: χ2 = 6.66, p < .010). 
Bacterial growth also significantly peaked in infections with the un-
supplemented wild type when considering the entire growth trajec-
tories and not only a single time point (Fig. S1), thereby confirming 
the above pattern.
One possible explanation for the absence of a linear relationship 
between pyoverdine availability and in vivo growth is that pyoverdine 
might not be required for bacteria to thrive within the host. However, 
two control experiments speak against this hypothesis. First, the 
growth of a pyoverdine- deficient knockout strains was significantly 
impaired in host infections compared to the wild type (Kruskal–Wallis 
test: χ2 = 7.54, p < .001; Figure 2). Second, ex vivo growth of wild- 
type bacteria in extracted haemolymph demonstrated significant iron 
limitation and high pyoverdine production in this medium (Fig. S2). 
Altogether, these results indicate that pyoverdine is important for iron 
scavenging and growth within the larvae.
3.3 | Pyoverdine availability affects host responses
To investigate whether bacteria and/or pyoverdine availability triggers 
variation in host responses, we tracked growth of a wild- type strain 
ex vivo in haemolymph extracts from larvae previously primed under 
different conditions. Ex vivo bacterial growth in haemolymph indeed 
significantly differed depending on the infection history of the lar-
vae (Figure 3; Kruskal–Wallis test: χ2 = 10.59, p = .014, including the 
pyoverdine manipulation regimes and the saline control). Specifically, 
bacteria showed significantly lower growth in haemolymph from 
wild- type- primed larvae than in haemolymph from saline- primed lar-
vae (χ2 = 4.11, p = .043). Furthermore, we found a significant negative 
association between the availability of pyoverdine in the priming in-
ocula and the subsequent ex vivo bacterial growth (Figure 3; Kendall’s 
τ = −.21, p = .023). Control experiments revealed that a significant 
host response can be triggered by multiple stimuli: priming larvae 
F IGURE  1 Our treatment regime significantly affected pyoverdine availability (a) and bacterial growth (b) in linear ways. To capture the 
dynamics of pyoverdine availability (first 8 hr) and growth (24 hr) in bacterial cultures, we used integrals (i.e. area under the curve) for analysis. 
Nonlinear patterns in (a), for example for the 10 μM and 20 μM pyoverdine supplementations, can arise because bacteria plastically adjust their 
pyoverdine production level according to their need (Kümmerli et al., 2009), such that de novo production and supplementation can balance 
each other out over time. Symbols and error bars represent mean estimates and 95% confidence intervals, respectively, across four independent 
replicates
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with non- pyoverdine- producing bacteria, pyoverdine alone or heat- 
killed bacteria all resulted in a similarly increased response relative 
to the saline priming (Kruskal–Wallis test comparing pooled control 
treatments versus the saline treatment: χ2 = 8.24, p = .004). Overall, 
our findings suggest that haemolymph primed with bacteria has a 
growth- inhibiting effect on P. aeruginosa and that this effect can vary 
plastically over time in response to pyoverdine availability.
3.4 | Pyoverdine availability affects the expression of 
other virulence factors
In addition to its function as a siderophore, pyoverdine is also a 
signalling molecule, which controls its own production and the 
synthesis of two other virulence factors, namely protease IV and 
exotoxin A (Beare, For, Martin, & Lamont, 2002; Lamont et al., 2002) 
(Figure 4). It is therefore well conceivable that the experimental ma-
nipulation of pyoverdine availability also affects the expression of 
these other virulence factors. To test this hypothesis, we performed 
in vitro qPCR experiments, following the expression of the genes 
pvdS, pvdA, prpL and toxA across three levels of pyoverdine avail-
abilities and two time points (early- and mid- exponential phase). We 
examined these time points because pleiotropy relatively early in 
the growth cycle is likely to have the biggest effect on subsequent 
pathogen growth and virulence. The four genes code for the sigma 
factor PvdS (the main regulator of all three virulence factors), PvdA 
(enzyme involved in pyoverdine synthesis), protease IV and exotoxin 
A (Figure 4). Taking the unsupplemented wild- type bacteria growing 
in our standard iron- limited medium as a reference, we found that 
the addition of iron dramatically downregulated the expression of 
all four genes (Table 1). This suggests that all three virulence factors 
(pyoverdine, protease IV and exotoxin A) are significantly expressed 
under the imposed iron- limited conditions (see also Ochsner, 
Wilderman, Vasil, & Vasil, 2002). Next, we examined whether gene 
expression levels change as a function of pyoverdine availability. 
We found that pyoverdine manipulation either did not affect gene 
expression or resulted in the downregulation of interlinked genes 
(Table 1). As there were no marked differences in gene expression 
profiles between the early- and the mid- exponential growth phase, 
F IGURE  2 Pyoverdine availability has nonlinear effects on 
P. aeruginosa growth in G. mellonella larvae. Bacterial load (measured 
17 hr postinfection) peaked in infections with the unsupplemented 
wild type, while the supplementation of both gallium (blue) and 
pyoverdine (red) resulted in a significant drop of bacterial load. 
Infections with a pyoverdine- deficient strain also resulted in a 
significant growth reduction compared to wild- type infections, 
indicating that pyoverdine is important for growth in this host. 
Symbols and error bars represent mean estimates and 95% 
confidence intervals, respectively. Numbers on top show sample size 
for each treatment
F IGURE  3 Growth of P. aeruginosa in haemolymph extracted 
from primed larvae demonstrates context- dependent host effects. 
Fourteen hours prior to haemolymph extraction, larvae were primed 
with wild- type bacteria, either alone or supplemented with gallium or 
pyoverdine. Control larvae were primed with saline alone, pyoverdine 
alone, heat- killed wild- type bacteria or a pyoverdine- deficient strain. 
Haemolymph extracts were gentamicin- treated to kill previously 
inoculated bacteria, and growth assays were then performed with a 
gentamicin- resistant wild- type strain. Compared to the saline control, 
haemolymph primed with wild- type bacteria was significantly more 
refractory to subsequent bacterial growth, demonstrating a host 
response to infection. Moreover, we found a significant negative 
correlation between pyoverdine availability during the priming phase 
and the subsequent bacterial growth, indicating that pyoverdine 
is involved in triggering host responses. Symbols and error bars 
represent mean estimates and 95% confidence intervals, respectively. 
Numbers on top show sample size for each treatment
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we pooled the data to identify the genes that were significantly 
downregulated (Figure 4). These analyses revealed that the addi-
tion of gallium (10 μM) slightly but significantly reduced the expres-
sion of pvdS (t3
 = −10.55, p = .002) and pvdA (t3
 = −3.87, p = .031). 
The supplementation of pyoverdine (200 μM) significantly reduced 
the expression of pvdA (t3 = −17.95, p < .001) and toxA (t3 = −4.50, 
p = .020). Our results are promising from a therapeutic perspective, 
as they suggest that the manipulation of pyoverdine availability does 
not increase the expression of the interlinked virulence factors pro-
tease IV and exotoxin A, but rather has a neutral or even a negative 
effect on their expression.
3.5 | Relationship between pyoverdine 
availability and virulence
Our results presented above (Figures 2–4) show that the manipula-
tion of pyoverdine availability has nonlinear effects on bacterial load, 
triggers differential host responses and has slight pleiotropic effects 
on the expression of other virulence factors. How do these factors 
now all combine within the host and determine the overall level of 
virulence associated with pyoverdine manipulation? Overall, our ex-
perimental infections of G. mellonella larvae revealed a significant 
positive association between pyoverdine availability and virulence 
F IGURE  4 Manipulating pyoverdine availability has moderate effects on the pyoverdine signalling network, and generally leads to the 
downregulation of interlinked genes. Pyoverdine production is controlled by the alternative sigma factor PvdS that is itself negatively regulated 
by the ferric uptake regulator FUR, in response to intracellular iron levels. Pyoverdine modulates PvdS activity through a signalling cascade. 
Incoming iron- bound pyoverdine binds to its cognate receptor, thereby triggering the lysis of the membrane- bound antisigma factor FpvR, which 
binds and inhibits PvdS. In turn, membrane- released PvdS triggers increased transcription of pyoverdine synthesis genes, but also activates 
the expression of prpL (encoding the protease IV virulence factor) and toxR (coding for the ToxR regulator that then stimulates the expression 
of exotoxin A). Reduced pyoverdine availability (gallium supplementation, blue bars) moderately but significantly reduced pvdS and pvdA 
expression. Increasing pyoverdine availability (red bars) moderately but significantly reduced pvdA and toxA expression. Shown are mean values 
and standard errors across four replicates. Asterisks indicate significant gene expression changes relative to the unsupplemented wild type 
(p < .05). † indirect regulation via toxR regulator
98  |     WEIGERT ET al.
(Figure 5; Kendall’s τ = .71, p = .030). Larvae died earlier in infections 
supplemented with pyoverdine, but survived longer when gallium was 
added instead. However, the trend was not altogether monotonic: 
moderately increased pyoverdine availability (10 μM) significantly de-
creased rather than increased the virulence risk (parametric survival 
regression assuming Weibull distribution: coefficient = 0.082 ± 0.028, 
mean ± SE, z = 2.89, p = .004). Such low- pyoverdine- supplementation 
infections showed virulence levels comparable to those of unsupple-
mented infections involving the pyoverdine- deficient PAO1ΔpvdD 
mutant (coefficient = 0.0055 ± 0.028, z = 1.94, p = .846). The gallium- 
supplemented treatments were not ordered monotonically with 
respect to virulence, in that high (250 μM)- gallium- supplemented 
infections were no less virulent than intermediate (50 μM)- gallium- 
supplemented infections (coefficient = 0.043 ± 0.037, z = 1.18, 
p = .238).
4  | DISCUSSION
Our results show that the manipulation of pyoverdine, an important 
virulence factor of the opportunistic human pathogen P. aeruginosa, 
affects bacterial load in infections of G. mellonella larvae in complex 
ways, triggers differential host responses and influences the expres-
sion of other regulatorily linked virulence factors (Figures 2–4). Our 
findings have important consequences for recently proposed an-
tivirulence therapies, targeting pyoverdine- mediated iron uptake 
(Bonchi et al., 2014, 2015; Imperi et al., 2013; Kaneko et al., 2007; 
Ross- Gillespie et al., 2014), because complex interactions between 
bacterial load, host response and regulatory pleiotropy could result 
in unpredictable treatment outcomes (García- Contreras et al., 2014). 
We examined this possibility for our system and found an overall posi-
tive relationship between pyoverdine availability and virulence, but 
also notable deviations from a monotonic pattern. For instance, the 
supplementation of low levels of pyoverdine significantly decreased 
rather than increased virulence, with this treatment reaching virulence 
levels comparable to infections with the pyoverdine knockout strain 
(Figure 5).
Some of the discovered complex nonlinear associations between 
bacterial load, host response, pleiotropy and virulence warrant closer 
examination. For instance, why does increased pyoverdine availabil-
ity (50 μM and 250 μM supplementation regimes) increase virulence 
despite the fact that these treatments reduce bacterial growth in 
TABLE  1 Expression fold changes for P. aeruginosa genes involved in pyoverdine- mediated signalling
Growth Phase Gene
Supplementation regime
100 μM FeSO4  10 μM Ga(NO3)3 200 μM Pyoverdine
Mean SE Mean SE Mean SE
Early- exponential pvdS 0.0003 0.0002 0.3256 0.0199 0.7237 0.1719
pvdA 0.0001 0.0000 0.3442 0.0353 0.3675 0.0159
toxA 0.0544 0.0098 0.9063 0.0161 0.2154 0.0200
prpL 0.2321 0.0375 0.7072 0.3661 1.1106 0.0821
Mid- exponential pvdS 0.0003 0.0002 0.5167 0.0350 0.8273 0.0628
pvdA 0.0003 0.0002 0.7242 0.1163 0.4059 0.0775
toxA 0.0561 0.0092 1.1514 0.1412 0.6463 0.0519
prpL 0.0214 0.0046 0.3776 0.0896 0.3240 0.0143
Expression fold changes of pvdS (encoding the iron- starvation sigma factor PvdS), pvdA (coding for one of the pyoverdine synthesis enzymes), toxA (coding 
for exotoxin A) and prpL (encoding protease IV) are expressed relative to the unsupplemented PAO1 wild- type regime.
F IGURE  5 Relationship between pyoverdine availability and 
virulence, measured as mortality risk of larvae within each treatment. 
Overall, there is a positive correlation between pyoverdine availability 
and virulence with a notable exception. Supplementing the 
infection with 10 μM pyoverdine reduced virulence comparable to a 
pyoverdine- deficient mutant. Symbols and error bars represent mean 
estimates and 95% confidence intervals, respectively. Numbers on 
top show sample size for each treatment
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vivo (Figure 2) and results, in vitro at least, in the downregulation 
of the coupled virulence factor exotoxin A (Figure 4)? One possible 
explanation is that high pyoverdine supplementation triggers an ex-
cessive host response, which is not only curbing bacterial growth, 
but is also damaging the host itself. For instance, G. mellonella pro-
duces the iron chelator transferrin as part of its innate immune 
response (Han, Nam, Seo, & Yun, 2004), a protein which actively 
counteracts the iron- scavenging activities of pathogens (Miethke & 
Marahiel, 2007). Such a host response typically entails costs in terms 
of metabolic burden and autoimmune damage, and therefore must 
be appropriately calibrated (Day, Graham, & Read, 2007; Medzhitov, 
Schneider, & Soares, 2012). An overreaction from the host, perhaps 
in response to a high concentration of pyoverdine, could actually 
exacerbate, rather than reduce, virulence. Important to note is that 
although pyoverdine seems to induce a host response (Figure 3), it is 
not toxic itself, as larvae infected with pyoverdine alone all remained 
healthy (Figure 5).
Another complex association was that when increasing pyoverdine 
availability a little bit (10 μM) compared to the wild- type treatment, 
we observed a significant reduction of virulence (Figure 5). This drop 
can potentially be explained by a host response too, but this time by a 
well- calibrated one, which primarily harms the pathogen while being 
beneficial for the host. If this explanation holds true, then the sup-
plementation of moderate amounts of pyoverdine could represent a 
treatment that boosts host tolerance. Interestingly, treatments that 
increase host tolerance have, in addition to antivirulence approaches, 
been proposed as alternative ways to combat infections (Ayres & 
Schneider, 2012; Medzhitov et al., 2012; Vale et al., 2014, 2016).
Finally, we observed that infections with intermediate amounts 
of gallium (50 μM) were significantly less virulent than infections with 
the pyoverdine- deficient knockout strain (Figure 5). This suggests that 
this treatment has other effects, in addition to simply depriving sidero-
phores from pathogens. One explanation would be that gallium has 
some general toxicity towards bacteria beyond its role in inhibiting 
iron uptake (Bonchi et al., 2014). An alternative explanation, which 
is supported by our previous findings (Ross- Gillespie et al., 2014) but 
also the qPCR data (Figure 4), is that intermediate gallium levels main-
tain pyoverdine synthesis, while high gallium levels completely stall 
the production. This steady production likely imposes a twofold cost 
on bacteria: gallium does not only prevent pyoverdine- mediated iron 
uptake, but also induces continuous replacement of pyoverdine, which 
likely demands a high metabolic investment for very little reward (be-
cause pyoverdine is quenched by gallium once secreted). Given the 
ubiquity of linkages and feedback loops in the genetic architecture of 
bacteria (Dumas, Ross- Gillespie, & Kümmerli, 2013; Fazli et al., 2014; 
García- Contreras et al., 2014; Nadal Jimenez et al., 2012), such fea-
tures are likely important contributors to nonadditive effects between 
pathogen behaviour, fitness and virulence.
Given the complexities of host–pathogen relationships we have 
highlighted in this study, what could be the evolutionary conse-
quences for antivirulence therapies? The central tenet of this ap-
proach was that disarming rather than killing pathogens should induce 
weaker selection for resistance because it exerts only minimal effects 
on pathogen fitness (André & Godelle, 2005; Pepper, 2008; Rasko & 
Sperandio, 2010; Stanton, 2013). Our study demonstrates that an-
tivirulence approaches can in fact substantially modulate pathogen 
fitness (Figure 2; see also Liu et al., 2008), which clearly offers nat-
ural selection the opportunity to favour pathogen variants that are 
partially or fully resistant to the treatment (see Maeda et al., 2012; 
Ross- Gillespie et al., 2014; Allen et al., 2014; for detailed discussion). 
One obvious evolutionary response of pathogens in response to vir-
ulence factor quenching is to overproduce the virulence factor in 
question in order to outpace the quenching activity of the drug. Our 
results indicate that such an adaptation could affect the host in two 
different ways. If the increase in virulence factor production is sub-
stantial, this could lead to the evolution of a more virulent pathogen, 
which causes increased damage to the host in the absence of the 
treatment. Conversely, if the increase in virulence factor production 
is relatively small, then it could positively stimulate host responses, 
which in turn could curb virulence. Evolutionary responses leading to 
increased virulence factor production would likely involve the modifi-
cation of regulatory elements. As evidenced by our study, regulatory 
elements can not only affect the expression of the targeted virulence 
factor, but also modify the expression of additional linked virulence 
factors in the same regulatory network (see Figure 4). How exactly 
such regulatory linkage would alter global virulence factor expression 
profiles of a pathogen in a host and how this feeds back on virulence 
cannot easily be foreseen, and might vary in response to the specific 
host stimuli present in an infection (Park et al., 2014). Finally, there 
might also be variation between host individuals regarding the ex-
tent to which they can cope with altered virulence factor expression. 
Conceivably, for an immunocompromised host even a minor overex-
pression of virulence factors might be fatal, whereas a healthy host 
might be more tolerant and easily able to cope with higher virulence 
factor levels. Taken together, our considerations show that we still 
have very limited understanding of the evolutionary consequences of 
antivirulence therapies. There is definitely a great need for controlled 
experimental evolution studies that measure selection pressures, 
adaptation patterns and host responses at both the proximate and 
ultimate level.
Given our dwindling supply of new antimicrobials, and the increas-
ing prevalence of resistance to those we already have (Fischbach & 
Walsh, 2009; Levy & Marshall, 2004), creative approaches such as an-
tivirulence therapies are certainly required (Perron, Inglis, Pennings, & 
Cobey, 2015; Ross- Gillespie & Kümmerli, 2014). To turn these ideas 
into effective and robust clinical therapies, however, we must delve 
deeper into the complexity of host–pathogen systems.
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